Messenger

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Cell, Colorectal cancer, Life, Biomarker, Artificial intelligence, Breast, Cancer, AI, Messenger, Bladder cancer, Inflammation, Machine learning, Nike (company), OTC, Breast cancer, Vaccine

SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market.

Key Points: 
  • SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market.
  • The mRNA biomarkers uncovered by Ludwig are a sensitive dynamic genetic signal associated with cancer that opens the door for the company to participate in the emerging billion dollar diagnostic cancer screening market.
  • This test uses cutting edge machine learning artificial intelligence (AI) applied by Dr. Kyle Ambert PhD.
  • Dr. Ambert has extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics.

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Mother, Research, Breast milk, Conference call, Development, Bill, Webcast, COVID-19, SAN, VOC, GI, Messenger, XBB, NHP, SARS-CoV-2, Insurance, Investment, Clinical trial, Antibody, Safety, Vaxart, Nextgen, Vaccine, FDA, Food, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.
  • Financial Results for the Full Year Ended December 31, 2023
    Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
  • Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022.
  • The Vaxart senior management team will host a conference call to discuss the business update and financial results for the full year 2023 today, beginning at 4:30 p.m.

IMUNON Files IND Application to Begin Human Testing of IMNN-101

Retrieved on: 
Wednesday, March 13, 2024
Drug discovery, COVID-19, Vaccine, DNA, Messenger, SARS-CoV-2, Trial of the century, IND, Infection, Immunity, Safety, Immunoglobulin G, FDA, Food

LAWRENCEVILLE, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for IMNN-101 for a Phase 1 clinical study with a seasonal COVID-19 booster vaccine. Following acceptance by the FDA, enrollment in this human proof-of-concept study is expected to begin in the second quarter of 2024.

Key Points: 
  • Following acceptance by the FDA, enrollment in this human proof-of-concept study is expected to begin in the second quarter of 2024.
  • The primary objectives of the Phase 1 study are to evaluate the vaccine safety, tolerability and neutralizing antibody response and its durability in healthy adults.
  • “We are delighted to have completed the work necessary to file this IND application and look forward to demonstrating proof-of-concept for our PlaCCine platform in COVID-19.
  • We’re looking forward to generating the proof-of-concept data necessary to begin these dialogues,” Mr. Tardugno added.

Cartesian Therapeutics Announces New Employment Inducement Grants

Retrieved on: 
Thursday, April 4, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Messenger, Employment, Therapy

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees.

Key Points: 
  • Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees.
  • The options are exercisable for an aggregate of 765,000 shares of the Company’s common stock.
  • Each of the four options was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors.
  • The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Messenger, Conference, Therapy

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m.

Key Points: 
  • Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m.
  • ET.
  • A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com , where an archived replay of the event will also be available for a limited time.

Takara Bio transforms single-cell landscape with new large-scale NGS profiling system for oncology biomarker discovery

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Cell, NGS, Biomarker, RNA, ABRF, Messenger, Head, AACR, Chemistry, Neoplasm, Booth, RNA-Seq, WGA, SNV, Annual general meeting, CNV, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.
  • Existing whole-genome amplification (WGA) technologies currently process 96–384 single cells per plate; the Shasta system increases WGA throughput to 1,500 cells per run.
  • In March, Takara Bio USA delivered instruments and NGS kits to early-access users, who have started producing results with the system.
  • We have two other projects in the lab where we want to do a full set of profiling of our entire model system.

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

Retrieved on: 
Tuesday, April 2, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Strategic Innovation Fund, Disease, Partnership, Vaccine, RNA, Messenger, MLE, National Research Council, Government, CAD, VBI

In preclinical studies, VBI’s MLE candidates generated strong B-cell and T-cell signals compared to those seen with other mRNA vaccines tested.

Key Points: 
  • In preclinical studies, VBI’s MLE candidates generated strong B-cell and T-cell signals compared to those seen with other mRNA vaccines tested.
  • The technology platform also offers potential for streamlined manufacturing timelines, similar to other mRNA vaccines.
  • “We are grateful for the continued support of our long-term partners in the Canadian government, and are pleased to extend our work together to investigate our novel MLE platform, which we think has the potential to revolutionize particulate vaccines,” said Jeff Baxter, President and CEO of VBI.
  • Consistent with the strategic intent of the original agreement, development will primarily focus on platform development and will also include a pan-coronavirus MLE candidate to contribute toward future epidemic and pandemic preparedness.

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, Moderna, Messenger, Patient, BX, MRNA, Vaccine

Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $750 million to fund Moderna’s influenza (“flu”) program.

Key Points: 
  • Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $750 million to fund Moderna’s influenza (“flu”) program.
  • This landmark collaboration is another example of our long-standing strategy to partner with the world’s leading life science companies to advance their critical path vaccines, medicines and medical technologies to patients,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences.
  • Achieving this ambition requires substantial investment in late-stage studies and we are excited to welcome Blackstone and their innovative financing model.”
    This new collaboration continues Blackstone Life Sciences’ work and support for many of the world’s leading and most innovative biopharmaceutical and medical technology companies.
  • Blackstone seeks to provide customized financing solutions for companies across therapeutic areas to support mission critical scientific innovation and advance important products to patients.

Nylas Partners with Seasalt.ai to Help Asia Pacific and Japanese Organizations Unlock Conversational AI and Developer Productivity

Retrieved on: 
Wednesday, March 27, 2024
Apps, Applications, Technology, Mobile, Wireless, Security, Software, Networks, Internet, Data Management, Artificial Intelligence, Messenger, Algorithm, Communication, Partnership, Omnichannel, AI, WhatsApp, Organization, SMS, API, Contact lens, Machine learning, Calendar, APJ, Sales

Additionally, customers will have access to dynamic AI capabilities to enhance customer conversations and satisfaction.

Key Points: 
  • Additionally, customers will have access to dynamic AI capabilities to enhance customer conversations and satisfaction.
  • Organizations are increasingly turning to AI-enabled solutions as a means to drive developer productivity while simultaneously providing better user experiences for their customers.
  • See instant time and cost savings by seamlessly deploying communications functionality and AI capabilities across various geographic regions, including Asia, Europe, and North America.
  • Through a strategic partnership with Nylas, Seasalt.ai significantly enhances the contextual depth of Contacts via conversational AI.